Long-term efficacy of canakinumab in hyperimmunoglobulin D syndrome


ÖZDEMİR IŞIK Ö., Karadag D. T., Tekeoglu S., YAZICI A., Cefle K., ÇEFLE A.

International Journal of Rheumatic Diseases, cilt.27, sa.1, 2024 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1111/1756-185x.14857
  • Dergi Adı: International Journal of Rheumatic Diseases
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Anahtar Kelimeler: canakinumab, hyperimmunoglobulin D syndrome
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Hyperimmunoglobulin D syndrome (HIDS) is a rare autoinflammatory disorder with autosomal recessive inheritance. It is caused by specific mutations in the mevalonate kinase gene (MVK). No treatment specific to HIDS has been approved to date; however, nonsteroidal anti-inflammatory drugs, steroids, colchicine, tumor necrosis factor-α inhibitors, and anti-interleukin-1 treatments are used, based on case reports and observational studies. Herein, we report a case with recurrent fever and arthritis attacks who did not respond to anakinra and was successfully treated with canakinumab. Long-term remission was achieved without any side effects with 300 mg canakinumab treatment every 4 weeks for 5 years.